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ABSTRACT 
Sperm-specific phospholipase C zeta (PLCζ) is widely considered to be the physiological 
stimulus that evokes intracellular calcium (Ca2+) oscillations that are essential for the initiation 
of egg activation during mammalian fertilization. A recent genetic study reported a male 
infertility case that was directly associated with a point mutation in PLC C2 domain, where 
an isoleucine residue had been substituted with a phenylalanine (I489F). Here in, we have 
analysed the effect of this mutation on the in vivo Ca2+ oscillation-inducing activity and the in 
vitro biochemical properties of human PLC. Microinjection of cRNA or recombinant protein 
corresponding to PLCζI489F mutant at physiological concentrations completely failed to cause 
Ca2+ oscillations and trigger development. However, this infertile phenotype could be 
effectively rescued by microinjection of relatively high (non-physiological) amounts of 
recombinant mutant PLCI489F protein, leading to Ca2+ oscillations and egg activation. Our in 
vitro biochemical analysis suggested that PLCI489F mutant displayed similar enzymatic 
properties but dramatically reduced binding to PI(3)P and PI(5)P-containing liposomes 
compared to wild-type PLC. Our findings highlight the importance of PLC at fertilization 
and the vital role of the C2 domain in PLC function, possibly due to its novel binding 
characteristics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 In mammalian oocytes (eggs), the fertilizing sperm evokes a series of pre-programmed 
biochemical and morphological events collectively known as ‘egg activation’. It is now well 
established in all mammalian species studied, that the earliest step of egg activation involves 
marked increases in the levels of the egg cytosolic calcium concentration [Ca2+], which are 
both necessary and sufficient for activation and early embryonic development [1-3]. Despite 
recent controversies, a gamete-specific phospholipase C (PLC) isoform, PLC is widely 
considered as the physiological stimulus that induces the characteristic series of large 
cytoplasmic Ca2+ transients, known as Ca2+ oscillations, within the fertilizing oocyte [3-8]. 
Sperm PLC is delivered from the fertilizing sperm into the egg cytoplasm, catalyses the 
hydrolysis of its membrane-bound phospholipid substrate, phosphatidylinositol 4,5-
bisphosphate (PIP2), triggering the cytoplasmic Ca2+ oscillations through the inositol 1,4,5-
trisphosphate (InsP3) signaling pathway [3, 4, 9]. PLC appears to be the smallest currently 
known mammalian PLC isozyme, with the most basic domain organization amongst all PLC 
isoforms. PLC consists of four EF hand domains at the N-terminus, the characteristic X and 
Y catalytic domains in the centre, followed by a C-terminal C2 domain [4, 9]. Thus, PLC 
possesses a similar domain organization to PLC1 with the remarkable exception that it lacks 
an N-terminal pleckstrin homology (PH) domain [9]. The notable lack of a PH domain, makes 
it unclear how this sperm-specific PLC isoform directly interacts and targets biological 
membranes. A recent report, suggested that the N-terminal lobe of the EF-hand domain of 
PLC together with its positively charged XY-linker, has an essential role to provide a tether 
that facilitates proper PIP2 substrate access and binding in the PLC active site [10]. However, 
the exact mechanism that PLC targets the PIP2-containing membrane is still unknown. 
  Evidence for the clinical importance of PLC has been provided by studies that have 
directly linked reduced expression levels and abnormal forms of PLC with male infertility [5, 
11-15]. A very recent genetic study, using whole-exome sequencing analysis identified a 
homozygous missense mutation in the PLC gene of two infertile brothers from Tunisia, 
presenting oocyte activation failure [8]. This mutation was located in the C2 domain of PLC, 
where an isoleucine at position I489 had been replaced with a phenylalanine (I489F), (Fig. 1A) 
[8]. Interestingly, this is the first male infertility-linked PLC point mutation to be reported 
within the C2 domain of PLC, a domain which although is well known to be essential for 
PLC function, its exact role still remains unclear. It was shown that I489F mutation results in 
some loss of Ca2+ oscillation-inducing activity of PLC in eggs, but the degree of loss of 
activity was not quantified and the poor ability of the PLC mutant to trigger Ca2+ oscillations 
was not extensively characterized [8]. 
 In the present study we introduced the infertility-linked PLC I489F mutation into 
human PLC sequence and we analysed the effect of this mutation on both the in vivo Ca2+ 
oscillation-inducing activity and the in vitro biochemical/enzymatic properties of human 
PLC. For comparison, cRNA encoding luciferase-tagged versions of wild-type and PLCI489F 
mutant or bacterially-expressed recombinant proteins were microinjected into unfertilised 
mouse and bovine eggs. Circular Dichroism (CD) spectroscopy was used to investigate whether 
the I489F mutation interferes with the proper folding of the C2 domain. The enzymatic and 
biochemical properties of PLCWT and PLCI489F mutant were analyzed using an in vitro 
[3H]PIP2 hydrolysis and liposome binding assays.  
 
MATERIALS AND METHODS 
Plasmid construction 
 Human PLCζ-luciferase in pCR3 vector [5] was subjected to site-directed mutagenesis 
(QuikChange II; Stratagene) to generate the PLCζI489F mutant. PLCζWT and PLCζI489F mutant 
were amplified by PCR from the corresponding pCR3 plasmid using Phusion polymerase 
(Finnzymes) and the appropriate primers to incorporate a 5’-SalI site and a 3’-NotI site and 
were cloned into a modified pET expression vector (pETMM41). The primers used for the 
amplification of PLCζWT and PLCζI489F mutant were: 5’-
CCTAGTCGACATGGAAATGAGATGGTTTTTGTC-3’ (forward) and 5’- 
CTAAGCGGCCGCTCATCTGACGTACCAAACATAAA-3’ (reverse). Similarly to the full  
-length PLC constructs, the C2 domains (480-608aa) of PLCζWT and PLCζI489F mutant were 
amplified by PCR from the aforementioned corresponding pCR3 plasmids using Phusion 
polymerase (Finnzymes)  and the appropriate primers to incorporate a 5’-SalI site and a 3’-
NotI site and were cloned into pETMM41 vector. The primers used for the amplification of 
C2ζWT and C2ζI489F mutant were: 5’-
CACCGTCGACATGCCAATTACACTTACAATAAGG-3’ (forward) and 5’-
CTAAGCGGCCGCTCATCTGACGTACCAAACATAAA-3’ (reverse). Successful 
mutagenesis and cloning of the above constructs was confirmed by dideoxynucleotide 
sequencing (Applied Biosystems Big-Dye Version 3.1 chemistry and model 3730 automated 
capillary DNA sequencer by DNA Sequencing & ServicesTM). 
 cRNA synthesis 
 Luciferase-tagged PLCζWT and PLCζI489F constructs were linearized by restriction 
digests and then cRNA was synthesized using the mMessage Machine T7 kit (Ambion) and a 
poly(A)tailing kit (Ambion), as per manufacturer instructions. 
 
Protein expression and purification 
 E.coli (BL21-CodonPlus(DE3)-RILP; Stratagene) cells were transformed with the 
appropriate pETMM41 construct and cultured at 37°C until the A600 reached 0.6. Then protein 
expression was induced for 18 hours at 16°C with 0.1 mM isopropyl β-D-
thiogalactopyranoside (IPTG; ForMedium). Induced cells were then harvested by 
centrifugation at 6,000 g for 10 minutes at 4°C and resuspended in ice-cold amylose column 
buffer [10 mM tris HC1 pH 7.4, 200 mM NaCl, l mM EDTA and protein inhibitor mixture 
(Roche)]. Then the resuspended cells were sonicated four times for 15 seconds on ice. After 20 
minutes centrifugation at 20,000 g at 4°C, to remove the insoluble proteins, the soluble MBP-
tagged fusion proteins were purified by affinity chromatography using amylose resin column 
following standard procedures (New England Biolabs). Eluted proteins were then dialyzed and 
concentrated using centrifugal concentrators (Sartorius; 10,000 molecular weight cut-off). 
 
SDS-PAGE and Western blot 
 Recombinant MBP fusion protein were separated by SDS-PAGE and immunoblot 
analysis was performed as described previously [10]. Proteins were probed with a monoclonal 
penta-His antibody (1:5,000 dilution). 
 
Preparation and handling of mouse oocytes 
 Mature MII oocytes (eggs) were collected from female MF1 mice (Envigo Ltd) of 6-8 
weeks old, 15 hours after injection with 10 IU human chorionic gonadotrophin (hCG). 
Approximately 48 hours before hCG injection mice were injected with 10 IU pregnant mare’s 
serum gonadotrophin. Following collection, cumulus cells were removed using hyaluronidase 
treatment and eggs were maintained in M2 media (Sigma Aldrich) under mineral oil at 37°C 
until use. Injected eggs were transferred for development in KSOM Media (Embryomax by 
Millipore). All animal work was conducted according to Home Office Licensing procedures 
and approved by the Animals Ethics Committee at Cardiff University.  
 
Preparation and handling of bovine oocytes 
 Ovaries were collected after slaughter from the local abattoir and transported to the 
laboratory at 24 oC in PBS (Sigma P4417) within 1 hour. Cumulus oocyte complexes were 
collected by slashing the surface of the ovary with a scalpel in Medium 199 – Hepes buffered 
and the solution was passed through a 100-micron mesh filter in order to retain the cumulus 
oocyte complexes (COC). COC were placed in maturation media for 22h [16]. After 
completion of maturation COC were vortexed for 3-4 min in hyaluronidase in order to isolate 
the mature eggs, which were immediately washed and transferred in M2 media until use. 
 
Protein microinjection and measurements of intracellular Ca2+ 
 Eggs were in incubated in M2 media containing Cal-520 AM (5 μM) for 30 minutes at 
37 oC before the experiment. Eggs were held in M2 for microinjection [17]. Recombinant 
PLCζWT and PLCζI489F mutant fusion proteins were diluted in injection buffer (120 mM KCl, 
20 mM Hepes, pH 7.4) prior to introduction into oocytes using a high pressure injection 
method. Alexa Fluor 594 (1 mM) was used as a loading control to ensure the equal protein 
volume injection. Eggs were imaged in HKSOM media using a Nikon TE2000 inverted 
epifluorescence microscope connected to a cooled intesified CCD camera (Photek,UK) and 
fluorescence was recorded by photon counting software (Photek,UK). In cases where luciferase 
expression was measured the fluorescence (to quantify Ca2+ changes) was recorded alternately 
using a 10 second switching cycle [18]. The fluorescence signal was normalised to relative 
fluorescence by plotting absolute fluorescence divided by basal level fluorescence (F/F0).  All 
egg experiments were conducted within a three (3) week period. 
 
cRNA microinjection and measurements of intracellular Ca2+ and luciferase expression 
 Eggs were held in M2 for microinjection. cRNA was diluted in injection buffer (120 
mM KCl, 20 mM Hepes, pH 7.4) and in the case of cRNA also mixed with 1 mM Oregon 
Green BAPTA dextran OGBD (Life Technologies) prior to introduction into oocytes using a 
high pressure injection method [17]. Bolus injection calculated the amount of injection solution 
microinjected that was approximately 3-5% of oocyte volume. Eggs were imaged in HKSOM 
media containing 100 μM luciferin using a Nikon TE2000 inverted epifluorescence microscope 
connected to a cooled intensified CCD camera (Photek,UK) and both luminescence and 
fluorescence were recorded by photon counting software (Photek, UK). Luminescence 
(quantifying luciferase expression) and fluorescence (quantifying Ca2+ changes) were recorded 
alternately using a 10 second switching cycle [18] with these 2 signals being plotted 
individually for each oocyte over the same time scale. The fluorescence signal was normalised 
to relative fluorescence by plotting absolute fluorescence divided by basal level fluorescence 
(F/F0) and luminescence was plotted as a running average over 5 minutes.  All egg experiments 
were conducted within a 3-month period. 
 
CD spectroscopy 
 CD spectra of MBP, MBP-C2WT and MBP-C2I489F were recorded on an Aviv model 
215 instrument (Aviv Biomedical Inc., Lakewood, NJ) using a 0.1-cm quartz cell at 4 °C. 
Proteins were dissolved in 100 mM NaF, 20 mM KH2PO4/NaOH, pH 7.0, at a concentration 
of ~ 0.15 mg/ml. Concentrations were determined based on the absorbance at 280 nm assuming 
extinction coefficients derived from the amino acid composition [19]. Secondary structure 
content was analysed using the CDsstr algorithm [20] as implemented on DichroWeb [21] 
using the SMP180 reference spectra [22]. 
 Thermal stability was monitored at 221nm in 0.5 °C intervals from 4 °C to 70 °C (MBP) 
or up to a maximum temperature when protein aggregation was observed as indicated by a 
sharp increase of the dynode voltage with settings resulting in an average heating rate of ~ 30 
°C/h. Apparent melting temperatures Tm and van't Hoff's enthalpies ΔHvH were estimated from 
non-linear curve fitting assuming a 2-state folded-to-unfolded transition as described [23] with 
the ellipticity of the unfolded state set as that observed for MBP. 
 
Molecular modelling 
 Structural models of MBP, MBP-C2WT and MBP-C2I489F were generated using 
SWISS-MODEL with the corresponding parts of the PDB coordinates 3mq9 (residues 5 to 
366) and 1djg (rat PLCδ1, residues 496 to 624) as templates [24]. 
 
PIP2 hydrolysis assays 
 The PIP2 hydrolytic activity of recombinant MBP-tagged PLC proteins was 
determined as described previously [5, 10, 25]. The final PIP2 concentration in the reaction 
mixture was 220 µM, containing 0.05 µCi of [3H]PIP2. For the assays examining the Ca2+ 
dependence of PLC enzymatic activity, the Ca2+ buffers were prepared by EGTA/CaCl2 
admixture, while in assays to determine the dependence on substrate PIP2 concentration, 0.05 
µCi of [3H]PIP2 was mixed with cold PIP2 to give the appropriate final concentration [10, 26]. 
Km and EC50 values of Ca2+ dependence for PIP2 hydrolysis for the MBP-tagged PLC 
recombinant proteins were determined by non-linear regression analysis (GraphPad Prism 5). 
 
Liposome preparation and binding assays. 
 Unilamellar liposomes were prepared as previously described [10, 26]. For the protein-
liposome binding experiments, liposomes (100 µg) were incubated with 1 µg of each MBP-
tagged recombinant protein for 30 min at room temperature and centrifuged for 5 hours at 4 
°C. Supernatants and pellets were analysed either by SDS-PAGE and Coomassie Brilliant Blue 
staining or by the [3H]PIP2 hydrolysis assay, as previously described [10]. 
 
RESULTS 
Microinjection of cRNA encoding PLCI489F mutant completely failed to trigger Ca2+ 
oscillations when expressed at physiological concentrations in mouse eggs 
 To investigate the impact of I489F mutation on the in vivo Ca2+ oscillation-inducing 
activity of human PLC, we used site-directed mutagenesis to generate the PLCζI489F mutant. 
To enable direct comparative analysis with PLCWT and to verify that this construct was 
faithfully expressed as protein in cRNA-microinjected unfertilized mouse eggs, we produced 
this mutant as a luciferase-fusion construct, as previously described [10, 26, 27]. 
Microinjection of cRNA encoding luciferase-tagged PLCWT (PLCWT-LUC) caused 
prominent Ca2+ oscillations in all injected eggs (4.0 spikes in the first hour of oscillating), 
similar to those observed during fertilization, following successful protein expression to a level 
indicated by a luminescence reading of 0.06 c.p.s., (Fig. 1B left panel, Table 1). In contrast, 
microinjection of cRNA corresponding to PLCζI489F-LUC mutant failed to cause any Ca2+ 
oscillations at equivalent protein expression levels (0.06 c.p.s.), (Fig. 1B right panel, Table 1). 
Interestingly, expression of PLCζI489F-LUC mutant at significantly higher levels (0.74 c.p.s.) 
led to low frequency Ca2+ oscillations (2.3 spikes in the first hour of oscillating), (Fig. 1C, 
Table 1), suggesting that overexpression of PLCζI489F-LUC, which leads to overload of this 
mutant within the egg cytoplasm, can induce Ca2+ release from intracellular stores. 
 
 
Microinjection of MBP-PLCζI489F protein is less effective at triggering Ca2+ oscillations in 
mouse eggs 
 PLCζWT and PLCζI489F mutant were then subcloned into the pETMM41 expression 
vector to allow prokaryotic expression of these constructs, as 6xHis-MBP-fusion recombinant 
proteins. We have previously demonstrated that NusA is a powerful fusion partner for PLC, 
significantly enhancing the bacterial expression, protein solubility, as well as the purified 
recombinant protein stability over time [5, 10]. In this study, we demonstrate for first time that 
in addition to NusA, MBP tag is an extremely effective protein tag for PLC. Our comparative 
experiments with NusA tag showed that MBP is an effective protein fusion partner for PLC 
preserving its stability over time (data not shown).  
Optimal protein production for these MBP-fusion PLC constructs required induction 
of protein expression with 0.1 mM IPTG for 18 h at 16 0C. Following bacterial expression in 
E. coli and isolation by amylose resin affinity chromatography, the purified recombinant 
proteins were analysed by SDS-PAGE and immunoblot analysis using an anti-His (penta-His) 
monoclonal antibody (Fig. 2A). The dominant protein band with mobility corresponding to the 
predicted molecular mass for MBP-PLCWT and MBP-PLCζI489F mutant was observed for both 
recombinant fusion proteins (~118 kDa). These major bands were also confirmed by 
immunoblot analysis by the penta-His antibody (Fig. 2A right panel). Some additional, fainter, 
low molecular weight bands could be observed, which were also detected by the penta-His 
antibody and were probably the result of protease degradation occurring during the various 
stages of protein expression and purification. Microinjection of MBP-PLCWT into mouse eggs 
at a concentration of 0.0375 mg/ml revealed that it possesses a potent ability to trigger 
cytoplasmic Ca2+ oscillations (Fig. 2B; upper panel), matching that observed after 
microinjection of native sperm extracts [28]. Microinjection of the MBP protein alone was 
unable to induce Ca2+ release. Interestingly, microinjection of MBP-PLCζI489F mutant protein 
at equivalent levels that MBP-PLCζWT triggered physiological Ca2+ oscillations (0.0375 
mg/ml), was either unable to induce any Ca2+ oscillations (13/23 eggs) or could only trigger 
very low frequency Ca2+ oscillations (10/23 eggs), (Fig. 2B; lower panel). 
 To investigate whether it was possible to rescue the low frequency Ca2+ oscillations, 
MBP-PLCζI489F recombinant protein was microinjected at higher levels. We found that a 2-fold 
increase in the amount of MBP-PLCζI489F mutant (0.075 mg/ml) microinjected into mouse eggs 
was able to rescue the defective Ca2+ oscillation-inducing phenotype and trigger egg activation, 
as indicated by cleavage of the 2-cell stage (Fig. 3). These findings agree with our previous 
observations, suggesting that overload of PLCζI489F mutant within the mouse egg cytoplasm, 
can induce Ca2+ oscillations. 
 MBP-PLCWT protein is more potent in triggering Ca2+ oscillations in bovine eggs than 
MBP-PLCζI489F 
 To examine whether our previous observations regarding the ability of PLCζI489F 
mutant to trigger Ca2+ oscillations in mouse eggs are consistent in eggs of a different species, 
we compared the abilities of MBP-PLCζWT and MBP-PLCζI489F recombinant proteins to induce 
Ca2+ oscillations in bovine eggs. The optimal concentration for MBP-PLCζWT to induce a 
physiological pattern of Ca2+oscillations in bovine eggs was 0.15 mg/ml. In contrast, 
microinjection of MBP-PLCζI489F mutant protein at this concentration was able to trigger very 
low frequency Ca2+ oscillations in all microinjected eggs (Fig. 4). 
 
I489F does not alter the folding and the thermal stability of PLC C2 domain 
 To investigate whether I489F mutation within the C2 domain of PLC interferes with 
the proper folding of this domain, we analysed the MBP-tagged wild type and mutant C2 
domains (C2WT and C2I489F) by CD spectroscopy. Attempts to produce an untagged or 6xHis-
tag version of the C2 domain of PLCWT using the bacterial expression system proved 
unsuccessful, as the protein appeared to be completely insoluble, accumulating into inclusion 
bodies. Thus, C2WT and C2I489F (Fig. 5A) were cloned into pETMM41 expression vector to 
allow bacterial expression of these domains as 6xHis-MBP-fusion recombinant proteins. The 
presence of MBP tag significantly enhanced the expression of soluble C2 domains and the 
affinity-purified MBP-tagged C2 domains after SDS-PAGE and immunoblot analysis using 
the penta-His antibody, displayed the predicted molecular mass (~59 kDa); (Fig. 5B). It is 
worth noting, that prior the CD experiments removal of the MBP moiety from the C2 domains 
was attempted but this resulted in rapid degradation of the proteins. Thus, the intact MPB-C2 
domains were used for our CD studies, while the MBP moiety alone served as a control for our 
experiments. Spectra recorded at 4 0C were indistinguishable from each other, but different 
from that of MBP alone (Fig. 6A). Deconvolution of the spectra resulted in 39 % α helix / 18 
% β strand and 35 % α helix / 24 % β strand for MBP by itself and the two fusion proteins, 
respectively. These values are in very good agreement with those of homology based models 
of MBP (41 % α helix, 17 % β strand) and a PLC C2 domain combined with MBP (35 % α 
helix, 27 % β strand). The thermal stability was measured by monitoring the CD signal at 
221nm (Fig. 6B). All samples showed a steep decrease in ellipticity. In contrast to MBP, the 
fusion proteins precipitated upon unfolding as indicated by an increase of light scattering. 
Assuming a two-state folded-to-unfolded transition and extrapolating to the ellipticity observed 
for unfolded MBP, fitting of the data resulted in melting temperature Tm = 60.5 ± 0.5 0C and 
van't Hoff's enthalpies of ~560 and ~250 kJ/mol for MBP and the two fusion proteins, 
respectively. For MBP, these values agree with those previously reported [29]. 
 
I489F does not alter the in vitro enzymatic properties of human PLC 
 We then examined the impact of I489F mutation on the in vitro enzymatic properties 
of PLC. To determine the specific PIP2 hydrolytic enzyme activities for PLCWT and 
PLCI489F a micellar [3H]PIP2 hydrolysis assay was used as previously described [10, 27, 30]. 
The histogram of Fig. 7A and Table 2 reveal that the enzymatic activities of PLCWT and 
PLCI489F were almost identical (960±43 vs 953±49 nmol/min/mg), suggesting that I489F 
mutation has no effect on the ability of PLC to hydrolyse in vitro PIP2. In order, to investigate 
the effect of I489F mutation on Ca2+ sensitivity of PLCζ enzyme activity we assessed the ability  
of PLCWT and PLCI489F to hydrolyse [3H]PIP2 at different Ca2+ concentrations ranging from 
0.1  nM to 0.1 mM. The resulting EC50 values for PLCWT (66 nM) and PLCI489F (60 nM) 
were very similar (Fig. 7B, Table 2). In addition, calculation of the Michaelis-Menten constant 
Km, for PLCWT and PLCI489F also yielded in comparable values (81 vs 93 µM), (Table 2), 
indicating that I489F mutation has no effect on the Ca2+ sensitivity or on the in vitro enzymatic 
affinity of PLC for its substrate, PIP2.   
 
I489F dramatically reduces the binding of PLC to PI(3)P and PI(5)P 
 The only specific binding partners for PLC C2 domain that have been in vitro 
identified up to date are PI(3)P and PI(5)P [31, 32]. To examine the binding properties of 
PLCI489F to PIP2, PI(3)P and PI(5)P we employed two different approaches, a liposome-
binding (pull-down) and a liposome-binding/enzyme assay, as previously described [10, 26]. 
For these experiments, we prepared unilamellar liposomes, which were composed of 
PC:CHOL:PE (4:2:1) with incorporation of either 1% PIP2, 5% PI(3)P or 5% PI(5)P. For 
diminishing the non-specific protein binding to highly charged lipids, the liposome binding 
experiments were performed in the presence of a near-physiological concentration of MgCl2 
(0.5mM) [26]. The MBP moiety alone served as the negative control for our experiments. As 
shown in Fig. 8, MBP did not exhibit any specific liposome binding in the absence or presence 
of PIP2, PI(3)P and PI(5)P, whereas our positive control MBP-PLCWT displayed robust 
binding to liposomes containing either 1% PIP2, 5% PI(3)P or 5% PI(5)P. On the other hand, 
MBP-C2WT showed significant binding only to liposomes containing either 5% PI(3)P or 5% 
PI(5)P. In contrast, although MBP-PLCI489F was able to bind strongly to liposomes containing 
1% PIP2, its binding to liposomes containing either 5% PI(3)P or 5% PI(5)P significantly 
diminished (Fig. 8). Similarly, MBP-C2I489F was unable to bind liposomes containing 5% 
PI(3)P or 5% PI(5)P. These findings clearly suggest that I489F mutation clearly affects the 
binding of PLC C2 domain to PI(3)P and PI(5)P. For more quantitative analysis, a liposome-
binding/enzyme assay, was employed to analyze the binding of MBP-PLCWT and MBP-
PLCI489F to PIP2, PI(3)P and PI(5)P. Thus, 1 µg of recombinant protein corresponding to 
MBP-PLCWT and MBP-PLCI489F were incubated with liposomes containing either 1% PIP2, 
5% PI(3)P or 5% PI(5)P. After centrifugation, the supernatant were separated for the 
precipitated liposomes and the PIP2 hydrolytic activity determined using the standard [3H]PIP2 
hydrolysis assay. Based on the % of the PIP2 hydrolytic activity pre- and post-liposome 
binding, we estimated the relative binding of each PLC protein to the different 
phosphoinositide specific-containing liposomes [10]. As shown at histograms in Fig. 9, the 
binding of PLCWT and PLCI489F to PIP2-containing liposomes was almost identical, while 
the binding of PLCI489F to PI(3)P- and PI(5)P-containing liposomes had been reduced by 
~50% compared to PLCWT, suggesting that I489F mutation indeed dramatically reduces the 
binding of PLC to PI(3)P and PI(5)P. 
 
DISCUSSION 
 Mounting experimental and clinical evidence strongly supports the notion that sperm-
specific PLC is the sole physiological stimulus of egg activation during mammalian 
fertilization [4, 8, 11-14, 33-36]. Sperm-delivered PLC triggers the repetitive Ca2+ oscillations 
within the fertilized egg, by catalysing the hydrolysis of PIP2 stimulating the InsP3 signalling 
pathway [3, 9]. Although PLC is the smallest PLC isoform with the most basic domain 
structure organization, its discrete biochemical properties contribute to its supreme 
effectiveness in triggering the Ca2+ signalling phenomenon within the fertilized mammalian 
eggs [9]. 
 The past few years, clinical reports have directly linked defects in human PLC with 
documented cases of male infertility. Firstly, Yoon et al., [11] reported a number of infertile 
patients presenting oocyte activation failure, providing evidence that was due to absence of 
reduced levels of PLC within their sperm [11]. Then, the first direct link between male 
infertility and a mutation on PLC gene came from a study that reported a mutation on the 
catalytic domain of PLC (H398P) of a patient who failed fertilization after ICSI [12]. 
Interestingly, another study reported a second PLC mutation on the same heterozygous 
infertile patient, also in the catalytic domain (H233L) [14]. Recently, Escoffier et al., [8] 
reported a homozygous missense mutation in the PLC gene of two infertile brothers from 
Tunisia, presenting egg activation failure [8]. This mutation was located in the C2 domain of 
PLC where an Ile had been replaced with a Phe residue (I489F), (Fig. 1A) making it the first 
PLC mutation located in a different domain than the catalytic.  
 Here, we introduced the infertility-linked I489F PLC mutation in human PLC 
sequence and we assessed the effects of this mutation upon the in vivo Ca2+ oscillation-inducing 
activity and the in vitro biochemical and enzymatic properties of human PLC. Our study 
provides evidence and extends the previous work of Escoffier et al., [8] by revealing that (i) 
PLCζ I489F mutation dramatically reduces the Ca2+ oscillation-inducing activity of PLC in 
mouse and bovine eggs (Figs 1B, 2B, 4). Although microinjection of physiological levels of 
PLC mutant are either unable or triggered very low frequency Ca2+  oscillations in mouse and 
bovine eggs, a 2-fold increase in the amount of PLC microinjected in mouse eggs was capable 
of rescuing the defective Ca2+ oscillation-inducing phenotype, triggering egg activation of these 
PLCI489F microinjected eggs (Fig. 3). This suggests that by overloading the egg with 
significantly higher amounts of this PLC mutant can lead to successful oocyte activation, 
explaining the infertility of the two heterozygous brothers carrying this mutation. (ii) CD 
spectroscopy showed that the I489F C2 mutation has no effect on the proper folding and the 
thermal stability of this domain (Fig. 6). This was consistent with our observations regarding 
the enzymatic properties of PLCI489F mutant, which were almost identical with the enzymatic 
properties of PLCWT (Fig. 7, Table 2), suggesting that I489F mutation has no effect on the 
ability of PLC to hydrolyse PIP2. (iii) More importantly, our liposome binding experiments 
revealed that I489F mutation dramatically reduces (~50%) the binding of PLC to PI(3)P and 
PI(5)P (Figs. 8, 9), two phosphoinositides, which have been previously reported to interact with 
PLC in vitro [31, 32]. To the best of our knowledge, PLC  C2 domain is the first C2 domain 
amongst the C2 domains of all PLC isoforms that it has been shown to directly interact with 
PI(3)P and PI(5)P, in vitro. Although it is difficult to predict which amino acid residues play a 
role on these interactions, we have shown that I489 is a key residue for efficient binding of 
PLC to both PI(3)P and PI(5)P. High resolution three-dimensional structure analysis of PLC 
C2 domain by X-ray crystallography could help to reveal the critical binding sites for these 
interactions. It is now also necessary to understand the physiological role of the binding of 
PLC to PI(3)P and PI(5)P and also to extensively search for any other unidentified membrane 
egg proteins, which might interact with the C2 domain of PLC, assisting with the proper 
localization and targeting of this enzyme within the egg cytoplasm. 
 It has been proposed, at least for mouse PLC, that its nuclear translocation ability 
regulates the cell-cycle dependent Ca2+ oscillations [3]. It is worth noting that there is no 
scientific evidence for the C2 domain playing a role in the nuclear sequestration of PLC, as it 
has been clearly demonstrated that the nuclear localization signal (NLS) of mouse PLC is 
located within the XY linker region, close to the start of the Y domain [3]. 
 Understanding the complex mechanism of action of PLC requires further 
investigation. However, based on our previous and recent findings we propose that after sperm-
egg fusion and the delivery of PLC from the sperm into the egg cytoplasm, the high Ca2+ 
sensitivity of this prototypic PLC is conferred by its EF hand domains, allowing it to be active 
at resting egg Ca2+ levels [27, 31, 37]. PLC may then associate with a specific intracellular 
membrane by interaction of the C2 domain with either PI(3)P, PI(5)P or another unidentified 
egg membrane protein. Finally, the positively charged XY linker together with the first EF 
hand domain provide a tether to facilitate proper PIP2 substrate access, in order the catalytic 
XY domain to proceed with the catalysis of the hydrolysis of PIP2 to produce InsP3 (Fig. 10) 
[10]. 
 In conclusion, the identification of the first male infertility-linked PLC point mutation 
located in the C2 domain of PLC, provides the first clinical support for the vital role of this 
domain on PLC function. As our study proposes, this is purely due to its novel binding 
properties of this domain to PI(3)P and PI(5)P or other unidentified egg factor. In addition, the 
identification of another male infertility-linked PLC mutation necessitates the use of 
recombinant PLC protein in a clinical setting with the aim to rescue such cases of oocyte 
activation failure. 
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TABLE LEGENDS 
Table 1 
 Properties of luciferase-tagged PLCWT and PLCI489F mutant expressed in unfertilised 
mouse eggs 
Ca2+-oscillation-inducing activity and luciferase luminescence levels (cps) in the 1st hour of 
spiking are summarized for mouse eggs microinjected with luciferase-tagged PLCWT and 
PLCI489F mutant. Results are expressed as means ±S.E.M. 
 
Table 2 
 In vitro enzymatic properties of MBP-tagged PLCWT and PLCI489F mutant 
Summary of specific enzyme activity, Km and EC50 values of Ca2+-dependence for PIP2 
hydrolysis, determined by non-linear regression analysis (GraphPad Prism 5), (see Fig. 7). 
 
 
 
 
 
 
 
FIGURE LEGENDS 
Figure 1 
 Effect of I489F mutation on Ca2+-oscillation-inducing activity of human PLC in mouse 
eggs  
(A) Schematic representation of human PLC domain organisation identifying the location of 
I489F mutation within the C-terminal C2 domain. (B, C) Fluorescence and luminescence 
recordings reporting the Ca2+ changes [fluorescence (black traces) and luciferase expression 
(red traces; luminescence) in cps respectively] in unfertilized mouse eggs following 
microinjection of cRNA encoding luciferase-tagged PLCWT and PLCI489F mutant (see also 
Table 1). 
 
Figure 2 
 MBP-PLCI489F recombinant protein fails to induce physiological pattern of Ca2+ 
oscillations in mouse eggs, when microinjected in equivalent concentration levels to MBP-
PLCWT 
 (A) SDS-PAGE of affinity-purified recombinant MBP-tagged PLCWT and PLCI489F proteins 
(2µg) analysed by 8% SDS-PAGE and Coomassie Brilliant Blue staining (left panel) or 
immunoblot analysis using the penta-His antibody (1:5,000 dilution); (right panel). (B) Patterns 
of Ca2+ oscillations in unfertilized mouse eggs following microinjection of MBP-PLCWT and 
MBP-PLCI489F recombinant proteins. F/F0 represents fluorescent intensity of Cal520 relative 
to baseline.  
 
Figure 3  
Microinjection of higher (non-physiological) levels of MBP-PLCI489F recombinant 
protein in mouse eggs induces physiological pattern of Ca2+ oscillations and triggers egg 
activation. 
 F/F0 represents fluorescent intensity relative to baseline. The right panel shows 2-cell stage 
mouse embryos 22-24h after injection of MBP-PLCI489F recombinant protein. 
 
 
 
 
Figure 4  
MBP-PLCWT recombinant protein has greater potency in triggering Ca2+ oscillations in 
bovine eggs compared to MBP-PLCI489F 
 Bovine eggs were injected with MBP-PLCWT recombinant protein (top trace) or MBP- 
PLCI489F protein (bottom trace) and Ca2+ oscillations recorded. F/F0 represents fluorescent 
intensity of Ca2+ dye relative to baseline.  
 
Figure 5  
Expression of wild type and I489F mutant PLC C2 domains as MBP-tagged 
recombinant proteins  
(A) Schematic representation of the MBP fusion protein PLC C2 domains with numbers 
denoting their amino acid coordinates. (B) SDS-PAGE of affinity-purified recombinant MBP-
tagged PLC C2 domains (1µg) analysed by 10% SDS-PAGE and Coomassie Brilliant Blue 
staining (left panel) or immunoblot analysis using the penta-His antibody (1:5,000 dilution); 
(right panel). 
 
Figure 6  
CD analysis of MBP and MBP-tagged PLC C2 fusion proteins  
(A) CD spectra were recorded at 4 oC for MBP (black), MBP-C2WT (blue) and MBP-C2I489F 
(red). (B) Thermal stability was monitored at 221nm upon heating. In contrast to MBP, the 
fusion proteins precipitated at ~ 63 oC. Dashed lines represent best fits assuming a two-state 
unfolding mechanism and an ellipticity of the unfolded state common with MBP. 
 
Figure 7 
I489F mutation does not affect the in vitro enzyme specific activity and the Ca2+ sensitivity 
of PLC  
(A) PIP2 hydrolysis enzyme activity of MBP-PLCWT and MBP-PLCI489F obtained with the 
standard [3H]PIP2 hydrolysis assay. Values are means ± S.E.M. (n=4), using two different 
preparations of recombinant protein and each experiment was performed in duplicate. (B) 
Effect of various [Ca2+] on the normalized activity of MBP-PLCWT and MBP-PLCI489F 
recombinant proteins. For these assays, values are ± S.E.M. (n=4), using two different batches 
of recombinant proteins and with each experiment performed in duplicate (see Table 2). 
 
Figure 8  
I489F mutation reduces the binding of PLC to PI(3)P and PI(5)P containing liposomes 
Liposome ‘pull-down assays’ of MBP-tagged PLCWT and PLCI489F proteins. Unilamellar 
liposomes containing either PIP2 (1%), PI(3)P (5%), or PI(5)P (5%) were incubated with PLC 
recombinant proteins. Following liposome centrifugation, both the supernatant (s) and 
liposome pellet (p) were subjected to SDS-PAGE and Coomassie Brilliant Blue staining. 
 
Figure 9  
Quantitative analysis suggest that I489F mutation reduces ~50% the binding of PLC to 
PI(3)P and PI(5)P containing liposomes  
Normalized binding of MBP-PLCWT and MBP-PLCI489F recombinant proteins to unilamellar 
liposomes containing (A) 1% PIP2, (B) 5% PI(3)P and (C) 5% PI(5)P. Following 
centrifugation, the supernatants were assayed for their ability to hydrolyse PIP2 in vitro, using 
the standard [3H]PIP2 hydrolysis assay, (n=4±SEM, using two different preparations of 
recombinant protein). Based on the % of the PIP2 hydrolytic activity pre- and post- liposome 
binding the relative binding of each PLC protein to the liposomes was determined. Significant 
statistical differences (asterisks) were calculated by an unpaired Student’s t-test; ***P < 
0.0005, (GraphPad, Prism 5). 
 
Figure 10  
Schematic illustration of a proposed intracellular targeting mechanism of PLC  
Our study suggests that association of PLC with a specific vesicular membrane may be 
mediated by interaction of the C2 domain with PI(3)P, PI(5)P or an as yet unidentified 
membrane protein. Then, association of PLC with the negatively-charged PIP2 involves 
electrostatic interactions with the positively-charged 1st EF-hand domain and the XY-linker 
region. The catalytic XY domain subsequently proceeds with the enzymatic cleavage of PIP2. 
The high Ca2+ sensitivity of the enzyme is conferred by the EF hand domain enabling PLC to 
be active at resting nanomolar Ca2+ levels (Figure modified from [10]). 
 
 
 
 
TABLES 
Table 1 
 
 
Construct 
 
 
Pipette cRNA 
concentration 
(μg/μl) 
 
Number of 
eggs 
injected 
 
 
Number of 
eggs 
oscillating 
Mean 
number of 
spikes 1st hr 
of spiking 
 
Average 
expression in 
1st hr of 
spiking (cps) 
 
PLCWT-LUC 
 
0.015 20 19/20 4 ± 0.290 
 
0.06 ± 0.007 
 
PLCI489F-LUC 
 
0.015 19 1/19 0.15± 0.016 
 
0.06 ± 0.004 
 
PLCI489F-LUC 0.1 16 
 
15/16 2.3 ± 0.250 
 
0.74 ± 0.038 
 
 
Table 2 
 
PLC protein PIP2 hydrolysis enzyme activity 
(nmol/min/mg) 
Ca2+ dependence 
EC50 (nM) 
 
 
Km (M) 
 
PLCWT 960±43 66 81 
PLCI489F 953±49 60 93 
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